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Despite substantial survival gain in colorectal carcinoma (CRC)
with the larger use of adjuvant chemotherapy, nearly half of
patients develop metastatic disease. Most of them are not
amenable to surgical resection and are therefore proposed
systemic chemotherapy as palliative treatment. Chemotherapy has
demonstrated its ability to improve both survival and quality of
life (NGTAP, 1992; Scheithauer et al, 1993; Glimelius et al, 1994).
For 40 years, 5 Fluorouracil (5FU)-based regimens have remained
the standard first-line therapy. Significant improvement in
response rates have been demonstrated using folinic acid modula-
tion and dose escalation of 5FU with acceptable toxicity (ACCMP,
1992). Using optimal regimens (de Gramont et al, 1997), objective
tumour responses may be expected in 25–30% of cases and 
are generally of short duration. Second-line therapeutic options
have long been very disappointing (Ahlgren et al, 1991; Bertrand
et al, 1992) and until recently patients were usually not offered
alternative treatment after 5FU failure. However, encouraging
preliminary results have been recently published using continuous
5FU (Izzo et al, 1992) with response rates of 16%. Moreover, new
active drugs have recently demonstrated interesting anti-tumour
activity, namely irinotecan and oxaliplatin. Given as second-line
therapy in 5FU-resistant metastatic CRC patients, oxaliplatin
(trans-1-1,2-diaminocyclohexane oxalato-platinum) has demon-
strated synergistic activity with 5FU, with objective response rates
varying from 20–45% (Brienza et al, 1993; de Gramont et al,
1997). Peripheral neuropathy appears to be the main limiting
toxicity.
Irinotecan, a semi-synthetic derivative of camptothecin, is a
potent inhibitor of the DNA topoisomerase I and exerts its cyto-
toxicity through DNA replication arrest. In phase II studies,
irinotecan has demonstrated objective anti-tumour activity in
patients with documented 5FU-resistant metastatic colorectal
cancer, with response rates of 11–23%. An additional 40% of
patients experienced tumour stabilization for a median of 5 months
(Rougier et al, 1997). However, limiting toxicities of irinotecan
were delayed diarrhoea and severe neutropenia. Although its effi-
cacy is limited in term of response rate, second-line irinotecan was
recently shown to be superior to ‘best supportive care’ and ‘best
5FU-based regimens’, both in terms of survival and quality of life
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Summary Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU
failure, the most significant predictive parameters for tumour response, progression-free survival and toxicity. Between October 1992 and
April 1995, 455 patients with 5-FU resistant metastatic colorectal carcinoma entered four consecutive phase II trials. The first two studies
assessed tumour response, the other two were randomized studies which assessed the efficacy of racecadotril to prevent irinotecan-induced
diarrhoea. Due to homogeneous main eligibility criterias, data from those studies could be pooled for statistical analysis. Potential clinical and
biological predictive factors (PF) for toxicity, tumour growth control, e.g. response or stabilization and progression-free survival (PFS), were
studied in multivariate analysis. 363 patients were evaluable for response, 432 were evaluable for PFS, 368 for neutropenia and 416 for
delayed diarrhoea, respectively. Normal baseline haemoglobin level (Hb), time since diagnosis of colorectal carcinoma, grade 3 or 4
neutropenia or diarrhoea at first cycle and a low number of organs involved were the most PF for tumour growth control (P < 0.05). Significant
prognostic variables for PFS were WHO Performance Status, liver and lymph-node involvement, time since diagnosis, age and CEA value (P
≤ 0.02). Six groups of patients based on the number of unfavourable prognostic factors are presented. Baseline bilirubin, haemoglobin level,
number of organs involved and time from diagnosis were PF for neutropenia; PS, serum creatinine, leukocyte count, time from 5-FU
progression and prior abdominopelvic irradiation were PF for delayed diarrhoea (P ≤ 0.05). These PF should help clinicians to anticipate for a
given patient the probability to observe a response/stabilization or a toxicity. These results should also be prospectively confirmed in ongoing
or future trials using irinotecan, both as a single agent and in combination with other drugs. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1303, available online at http://www.idealibrary.com on in two large randomized trials (Cunningham et al, 1998; Rougier
et al, 1998). The present prognostic analysis on the cohort of 455
patients included in four consecutive phase II trials aimed to deter-
mine the predictive factors of efficacy and tolerance to irinotecan.
PATIENTS AND METHODS
Design of the clinical trials
Between April 1992 and October 1995, 455 patients have been
recruited in four consecutive phase II trials in order to assess the
clinical efficacy and/or tolerance to irinotecan (350 mg m–2 every
3 weeks) in metastatic CRC progressing on 5FU (Table 1).
The first phase II trial (F205) was conducted in 14 French
centres and included 213 patients. 73 patients have been retrospec-
tively selected with strictly documented disease progression after
prior 5FU treatment and then included in the present analysis. The
V222 study was aimed to confirm efficacy in a highly selected
population of 5FU-resistant metastatic CRC patients. 107 patients
entered this study in 25 European centres (seven countries). In
studies F220 and F221 the role of the new enkephalinase inhibitor
racecadotril (Tiorfan®) against diarrhoea was assessed as the
primary end-point. Colorectal patients resistant to 5FU were
randomly assigned to either prophylactic racecadotril or no
prophylactic treatment (F220) or to symptomatic treatment of diar-
rhoea with either a combination of loperamide and racecadotril or
high-dose racecadotril alone (F221). 275 patients entered these
studies (F220 + F221). No prophylactic treatment could demon-
strate any impact on the occurrence and severity of delayed diar-
rhoea and the adjunction of racecadotril to loperamide or
high-dose racecadotril failed to show evident superiority over
loperamide alone. The inclusion of these patients in a study
assessing predictive factors for delayed diarrhoea was therefore
relevant. Because the assessment of efficacy was not the main
study end-point, patients without measurable disease were also
considered for study entry. This explains why the rate of patients
inevaluable for overall response rate is higher in these studies.
Finally, the benefits and toxicities were not different across all four
trials, which reasonably allowed us to pool the individual data.
Patients characteristics
The criteria required for inclusion in the present analysis were:
histologically proven metastatic CRC; documented progressive
disease after 5FU treatment (last chemotherapy course 1–6 months
ago at the time of progression); at least one bidimensionally
measurable target lesion; WHO PS ≤2; age < 75 years; neutrophils
³2000 mm–3; platelets ³ 100 000 mm–3; serum creatinine 
≤ 135 mmol l–1: serum transaminases ≤2.5 normal (5 times in case
of liver metastases); serum bilirubin ≤1.5 times normal, normal
prothrombin level; life expectancy ³3 months; written informed
consent; and absence of central nervous system localization, prior
or concomitant other malignancy, chronic bowel disease or severe
concomitant medical condition. Some inclusion parameters
slightly differed from one trial to another, regarding the criteria for
assessment of progression (imaging only in study V222, imaging
and/or carcino embryonic antigen (CEA) level in others), the
minimal size of the measurable lesion (lung lesions <2 cm
accepted in study F 205 only), the required performance status
(PS) (patients with WHO PS 2 accepted in studies F205 and F222
but not in the other two), age limits (patients ≤70 years old in study
V222, ≤75 years old in the other studies), transminases and total
bilirubin levels, tumour burden (patients with bulky disease
excluded from all studies but F205).
Patients characteristics are listed in Table 2.
Assessment of efficacy and toxicity parameters
All responses observed by investigators (as well as radiological
progression on 5FU) have been reviewed by an Independent
Response Review Committee. Responses as well as the main
toxicity parameters (neutropenia and diarrhoea) were assessed
according to the WHO criteria. Tumour growth control was
defined by addition of responders and patients with stable disease.
The disease was considered as stable only if the duration of stabi-
lization was at least 3 months.
Statistical methods
The following multivariate analyses were performed: on the
evaluable population for response, on the treated population for
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Table 1 Design of the clinical trials
Study code Accrual Study design n
period (CPT11 350 mg m–2 3 weeks–1)
F 205 04/92–12/93 early phase II 73
V 222 01/95–06/95 confirmatory phase II 107
F 220 10/94–06/95 randomized phase II 136
F 221 11/94–10/95 randomized phase II 139
Total 455
Table 2 Patients characteristics (n = 455 patients)
Median age (years range) 58
(19–79)
Sex (M/F %) 60/40
Site of primary (%)
Colon 63
Rectum 26
Rectosigmoid 11
Median time since diagnosis (months) 15
WHO PS (%)
0 or 1 93
27
Median number of involved organs 2
Metastatic sites (% of patients)
Liver 81
Lung 38
Peritoneum 13
Number of prior chemotherapy regimens (%)
17 3
22 4
>2 3
Intent of prior chemotherapy (%)
Adjuvant only 13
Palliative only 68
Adjuvant + palliative 19
Best response to last prior palliative 5FU regimen (%)
CR/PR 11
NC 29
PD 53
Median time since last CT (months) 2
Median time since progression after 5FU (months) 1.5progression-free survival (PFS) and for toxicity after the first cycle
(diarrhoea and neutropenia).
A stepwise logistic regression was used to analyse response,
‘response and stabilization’ (tumour growth control) and toxicity
after the first cycle. Progression-free survival was calculated from
the first infusion of irinotecan to the first documentation of
progression, and was analysed using the Kaplan–Meier method.
We decided to choose this parameter rather than overall survival
since a significant proportion of patients received third-line
therapy, which could be a confounding factor.
Progression-free survival data were analysed using the Log-
Rank method (univariate analysis). In order to determine the inde-
pendent prognostic factors, a stepwise Cox’s proportional hazard
model for censored survival data was performed with the
prognostic factors which were found statistically significant in 
the univariate analysis.
The P values to enter and stay in the model were 0.10 and 0.11,
respectively. The variables common to all univariate analyses were
as follows: age, sex, liver involvement, lung involvement, peri-
toneal involvement, lymph-node involvement, WHO performance
status, primary tumour sites, number of involved organs, prior
radiotherapy, intent of prior chemotherapy, number of prior
chemotherapy regimens, response to prior 5FU, CEA value, time
since diagnosis of colorectal cancer, time since 5FU progression,
time since last chemotherapy, haemoglobin, neutrophils, WBC
counts, alkaline phosphatase, serum creatinine, LDH, total
bilirubin, transaminases at baseline and type of the study.
We also determined the baseline predictive factors for grade 3–4
neutropenia and grade 3–4 diarrhoea at first cycle. The same prog-
nostic variables were used in all the multivariate analyses except
for response + stabilization in which occurrence of either grade 3/4
neutropenia or diarrhoea during the first cycle was added. The
continuous variables were divided into categories using the quar-
tiles of the population. In a second step, for the logistic regression,
when the rate of events were similar for adjacent categories, these
categories were pooled. For censored data, the same methodology
was followed using the results of the relative risk.
Statistical analyses were carried out with the 6.08 version of
SAS® on VAX VMS®.
RESULTS
Efficacy analysis
Among the 455 5FU-resistant patients, 92 patients were not evalu-
able for tumour response, mainly (69/92) in F220/F221 studies
where the main study end-point was safety. Among 363 remaining
patients, the overall response rate was 12.9% (95% CI: 9.7–16.8%).
An additional 149 patients (41%) experienced tumour stabilization.
The median duration of response (from first infusion until progres-
sion) was 29 weeks, and that of tumour stabilization was 22 weeks,
leading to a median time to tumour progression of 18 weeks (4.2
months) in all treated patients. The median overall survival in the
entire population of patients (n = 455) was 41 weeks.
Univariate analysis of predictive factors
Only grade 3–4 diarrhoea at first cycle, WBC counts at baseline
and prior response to 5FU had a borderline correlation with
response in the univariate analysis. When objective ‘response or
stabilization’ was studied, five parameters became significant.
Time from diagnosis of CRC ³ 9 months (P = 0.0255), time from
last 5FU progression ³ 3 months (P = 0.06), haemoglobin level 
³ 12 g dl–1 (P = 0.0106), one organ involved (vs more than one) 
(P = 0.0044), occurrence of either grade 3 or 4 neutropenia or
diarrhoea at first cycle (P = 0.0758) were predictive of a higher
chance of response or stabilization.
A higher number of variables appeared to have a prognostic
value for progression-free survival. They are listed in Table 3.
Multivariate analysis of predictive factors
In the multivariate analysis of response no parameter remained in
the analysis at the 0.11 level. For response and/or stabilization only
haemoglobin level at baseline, time from diagnosis of CRC, occur-
rence of grade 3 or 4 neutropenia or diarrhoea at first cycle and the
number of organs involved remained predictive (Table 4).
The Cox stepwise multivariate analysis on PFS was performed
on 432 patients without missing data (covariates).
The variables were entered in the model in the following order:
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Table 3 Significant parameters for progression-free survival (PFS) after
CPT-11 treatment (univariate analysis) (n = 432 patients)
Parameter (associated to poorest PFS) Risk ratio P value
Age <58 years 1.313 0.006
Liver involvement 1.314 0.032
Lymph-node involvement 1.450 <0.001
Time since diagnosis of CRC to first infusion* 1.434 0.001
(months) <9
Time since 5-FU progression to first infusion* 1.230 0.040
(months) <1.5
Time since last chemotherapy to first infusion* 1.218 0.084
(months) <2.8
Neutrophil count (Gigal l–1) ³5.3 1.201 0.065
Transaminase (% of UNL) ³48 1.167 0.122
CEA (mg L–1) value ³19 1.44 0.002
Haemoglobin (g dl–1) <12 1.31 0.011
Alkaline phosphatase (% of UNL) ³217 1.632 0.001
Number of organs involved >3 1.652 0.020
WHO performance status ³2 1.430 0.07
UNL = upper normal limit; *of irinotecan
Table 4 Significant parameters for response or stabilization in patients
under CPT-11 treatment (multivariate analysis) (n = 363 patients)
Covariate (class/reference) Odds ratio* P
Haemoglobin
<12 g dl–1 1
³12 g dl–1 1.811 0.026
Time from diagnosis
<9 months 1
³9 months 1.794 0.024
Grade 3 or 4 neutropenia or
diarrhoea at first cycle
No 1
Yes 1.661 0.041
Number or organs involved
11
>1 0.523 0.008
* >1 indicates favourable prognostic valuetime from diagnosis of colorectal cancer (³9/<9 months), age
(³58/<58), CEA (<19/>19 mg ml–1) lymph-node involvement
(No/Yes), WHO performance status (<2/³2) and liver involvement
(No/Yes). Because of a >10% rate of missing data, the variables
response to prior 5FU, LDH and SGOT were not included. After
the variable liver involvement, no other variable met the 0.10 level
for entry in the model. Six variables may therefore be regarded as
independent prognostic factors for progression-free survival:
WHO PS, liver involvement and lymph-node involvement, time
from first diagnosis of CRC, age and CEA value (<19/>19 mg
ml–1) (Table 5). Six prognostic groups for progression-free
survival have been defined based on the number of unfavourable
prognostic factors. The progression-free survival rates at 4 months
were calculated using the variables of the final model on 432
patients without missing data. They are reported in Table 6.
Figures 1 to 4 show the PFS curves in patients with 1, 2, 3 and 4
unfavourable prognostic factors, respectively. Those patients
represent the vast majority of the evaluable patients. Figures 5
shows the PFS curve of all the evaluable patients.
Toxicity analysis
Four hundred and sixteen patients were evaluable for delayed diar-
rhoea and 368 for grade 3–4 neutropenia, respectively. The overall
incidence of grade 3–4 neutropenia during first cycle was 23%.
The overall incidence of grade 3–4 delayed diarrhoea at first cycle
was 25%. The rates of grade 3–4 neutropenia and delayed diar-
rhoea stratified on the risk factors in multivariate analysis are
given in Tables 7 and 8.
Univariate analysis of predictive factors
368 patients were evaluable for neutropenia (19% of missing data)
and 416 for delayed diarrhoea.
Grade 3–4 neutropenia
The significant factors were: number or organs involved, time
since first diagnosis to first infusion of irinotecan, WHO perfor-
mance status, haemoglobin, CEA level, total bilirubin, alkaline
phosphatase, SGOT/SGPT.
Grade 3–4 delayed diarrhoea
The significant factors were: number or organs involved, time from
last chemotherapy to first infusion of irinotecan, WHO perfor-
mance status, neutrophils and WBC count at baseline, time elapsed
from last 5FU progression and prior abdomino-pelvic radiotherapy.
Multivariate analysis of predictive factors
Grade 3–4 neutropenia
Four factors were predictive of a higher risk of grade 3–4
neutropenia: low haemoglobin level at baseline, increased
bilirubin, number of involved organs and time since diagnosis to
first infusion of irinotecan <15 months (Table 7).
Grade 3–4 delayed diarrhea
The predictive factors for grade 3–4 delayed diarrhea were: WHO
performance status, WBC count at baseline, serum creatinine, time
elapsed since last 5FU progression and prior abdominopelvic
radiotherapy (Table 8).
For neutropenia or delayed diarrhoea, no subgroup of patients
with low (<10%) or high (>50%) risk could be determined by any
combination of variables.
DISCUSSION
Irinotecan is a new alternative in the treatment of metastatic CRC
after failure of a 5FU-based chemotherapy. In the large cohort of
patients presented here objective response rates after prior 5FU
and duration of response are very consistent with those obtained in
the first pivotal phase II trial published by Rougier et al (1997), as
well as in the study of Pitot et al (1997) where the modality of
administration of irinotecan was slightly different. The unusually
high number of patients not assessable for tumour response
(20.2%) is linked to the design of two out of the four studies,
where inclusion criteria were less restrictive. The overall median
survival was 41 weeks, which is interesting in such a poor
prognosis group of patients.
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Table 5 Risk factors for progression-free survival after CPT-11 treatment
(multivariate analysis) (n = 432 patients)
Covariate Risk P value
ratio*
WHO performance status
<2 1 0.014
2 1.72
Liver involvement
Absent 1 0.02
Present 1.43
Lymph-node involvement
Absent 1
Present 1.50 0.002
Time between diagnosis of CRC and
First infusion of irinotecan (months)
³9 1 0.002
<9 1.47
Age
³58 years 1 < 0.001
<58 years 1.53
CEA (mg ml–1)
<19 1 0.017
>19 1.36
* >1 indicates unfavourable prognostic value
Table 6 Expected 4-month progression-free survival according to the
number of prognostic factors
Number of 4-month expected
prognostic progression-free n of patients
factors* survival rate (%)
07 4 1 0
16 7 5 3
2 58 142
3 46 139
43 4 7 5
52 1 1 2
69 1
* The prognostic factors are: liver involvement, lymph-node involvement,
short time since first diagnosis to first infusion of irinotecan, age <58, poor
WHO performance status and elevated CEA valuePerformance status at diagnosis was a strong prognostic factor for
response in the Advanced Colorectal Cancer Meta-analysis Project
publication on Methotrexate modulation (ACCMP, 1994). In a
series of 554 patients with unresected liver metastasis from CRC
(Rougier et al, 1995), 226 (41.5%) of them received chemotherapy
and eight parameters have demonstrated a significant value for
survival: baseline PS, alkaline phosphatase, number of involved
liver segments, treatment with chemotherapy, presence of extra-
hepatic metastasis, right colon as the primary tumour site,
prothrombin level and resection of the primary lesion.
Since both responding and stable patients may have increased
survival and quality of life with chemotherapy (Scheithauer et al,
1993; Glimelius et al, 1994), we considered this group of patients
which demonstrate clinical benefits of treatment (Allen et al,
1998). This concept has been confirmed in two large phase III
studies where irinotecan demonstrated a superiority to either best
supportive care or to an infusional 5FU regimen in terms of overall
survival and symptom-free survival (Cunningham et al, 1998,
Rougier et al, 1998).
The results of the present multivariate analysis suggest that the
determination of different categories of pretreatment parameters
might help predict treatment benefit. First of all are baseline indi-
cators of high tumour burden, such as the detection of more than
one involved organ. They appear as predictors of both response or
stabilization and progression-free survival.
Haemoglobin levels are usually not considered as a marker for
tumour burden. Despite this, in our study they appear to be corre-
lated to both response or stabilization and progression-free
survival.
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Figure 1 Progression-free survival in patients with one unfavourable
prognostic factor (n = 53)
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Figure 4 Progression-free survival in patients with four unfavourable
prognostic factors (n = 75)
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Figure 5 Progression-free survival in all evaluable patients (n = 432)
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Figure 2 Progression-free survival in patients with two unfavourable
prognostic factors (n = 142)
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Figure 3 Progression-free survival in patients with three unfavourable
prognostic factors (n = 139)The second category of prognostic indicators involves indi-
vidual clinical covariates such as age and WHO performance
status, the latter parameter being of high predictive value for
progression-free survival. In the phase II study reported by
Rougier et al, the prognostic value of WHO performance status at
baseline for both tumour response and time to disease progression
was already noted. It is noteworthy that PS and tumour burden are
independent prognostic factors. The alteration of the performance
status might therefore not only reflect the presence of bulky
disease. Surprisingly, age >58 years is also predictive of a higher
chance of clinical benefit. Since it is an independent prognostic
factor, it is not well correlated with the duration of evolution of the
disease (time from diagnosis of CRC) but could be correlated with
other factors of tumour aggressiveness in younger patients that
were not assessed in this study. Another group of prognostic
factors is related to the previous evolution of the disease, as
reflected by the strong prognostic value for both response or stabi-
lization probability and progression-free survival of the elapsed
time between date of diagnosis of CRC and second-line
chemotherapy. The fact that prior response to 5FU-based
chemotherapy is of no prognostic value confirms that irinotecan
may be offered as second-line treatment in both 5FU-sensitive
and-refractory patients. This is supported by a study which
reported the overexpression of thymidilate synthase in tumours of
patients refractory to 5FU who were still sensitive to irinotecan
(Saltz et al, 1998).
The correlation between occurrence of WHO grade 3 or 4 diar-
rhoea after the first cycle of irinotecan and probability of tumour
response or stabilization suggests a correlation between anti-
tumour activity and systemic exposure to irinotecan and/or its
metabolites. Indeed, neutropenia and delayed diarrhoea have been
shown to be correlated with both irinotecan and SN-38 AUCs,
although the existence of a relationship between those parameters
and tumour response was not clearly demonstrated (Chabot et al,
1995; Canal et al, 1996).
Delayed diarrhoea and neutropenia are the most common
adverse events that might lead to discontinuation of chemotherapy.
In this analysis, neutropenia and delayed diarrhoea are well corre-
lated to the duration of evolution of the disease but also to the
tumour burden markers. Indeed, the number of organs involved is
a strong predictive factor for grade 3–4 neutropenia and hyper-
leukocytosis is associated with an increased risk of diarrhoea.
Liver function and mainly cholestasis must be cautiously taken
into account before the administration of irinotecan. Total bilirubin
is the most relevant predictor for the risk of neutropenia. This
could be consistent with a delayed elimination of irinotecan and/or
SN-38. A serum creatinine elevation UNL appears as a predictive
factor for diarrhoea. This could suggest the role of as yet unknown
active metabolites, or the possibility of renal excretion of a frac-
tion of the original compound itself. Finally, prior abdominopelvic
radiotherapy moderately increases the risk of diarrhoea. This
finding has also been reported (Rougier et al, 1997), but the
highest incidence and severity of delayed diarrhoea related to the
age of the patients (>65 years), which appeared to be statistically
significant is not confirmed in the present multivariate analysis in
which these patients represent approximately 25% of the overall
population.
From a clinical point of view, identifying different subgroups of
patients with predictive progression-free survival rates and esti-
mating the cost–benefit ratio, e.g. toxicity/clinical benefit ratio, in
a population of patients to be treated by irinotecan, is of great
interest. Indeed, the usefulness of this drug has been demonstrated
in second-line treatment after 5FU failure, in a multicentric
randomized trial where irinotecan (350 mg m–2 every 3 weeks)
was compared to best supportive care alone. In this trial, overall
survival was significantly improved by irinotecan with a substan-
tial gain in patients’ quality of life. The same irinotecan regimen
was compared to the best current ‘high-dose’ 5FU regimens and
resulted in significant improvement in progression-free as well as
overall survival. This drug has therefore become standard therapy
in this population of patients.
In spite of the methodological limits of this analysis on pooled
data, the main predictive factors for toxicity and efficacy herein
reported may be considered as useful guidelines for routine practice.
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Table 7 Results of multivariate analysis for grade 3–4 neutropenia at first
cycle: significant factors
Risk factor (n) Rate (%) of Multivariate analysis
grade 3–4 n = 368/455
neutropenia*
Odds ratio P
(95% confidence
interval)
Baseline bilirubin (% UNL)
<68 (n = 323) 15 1 <0.001
³68 (n = 103) 47 4.9
Baseline haemoglobin (g dl–1)
³12 (n = 308) 17.8 1
<12 (n = 136) 34.5 2.8 <0.001
Number of organs involved
≤3 (n = 418) 21 1
>3 (n = 27) 44 4.1 0.004
Time between diagnosis and first
infusion of irinotecan (months) 18.4 1
³15 (n = 217) 26.7 0.034
<15 (n = 224)
n = number of patients in the subgroup; *overall incidence of grade 3–4
neutropenia at first cycle = 23% (n = 445 patients)
Table 8 Results of multivariate analysis for grade 3–4 delayed diarrhoea at
first cycle
Risk factor (n)** Rate (%) of grade 3–4 Multivariate
diarrhea* n = 416/455
Risk ratio P
Performance status
0 (n = 229) 18 1
1–2 (n = 226) 31 2.5 0.0004
Creatinaemia (% ´ UNL)
<71% (n = 223) 19 1
³71% (n = 219) 31 2.9 0.0001
WBC values at baseline
<9.7 (n = 337) 22 1
³9.7 (n = 117) 32.5 1.9 0.014
Time from 5-FU progression to
first infusion of irinotecan (months) 21.5 1
<2.8 (n = 330) 32 1.85 0.02
³2.8 (n = 107)
Prior abdomino-pelvic irradiation 22 1
No (n = 342) 32 1.7 0.046
Yes (n = 113)
*Overall incidence of grade 3–4 delayed diarrhoea at first cycle = 25%;
**Number of patients in the subgroupCONCLUSION
This prognostic analysis has been performed on a large homoge-
neous population of 5FU-resistant metastatic CRC patients.
Although patients were selected for entry in clinical trials, the data
from this study are probably applicable to the overall population of
metastatic CRC treated with irinotecan while progressing after
5FU treatment. Irinotecan appears as efficient and indicated in
patients resistant to 5FU, more specifically in those with good
performance status, low tumour burden and without cholestasis. In
the other cases, since the potential clinical benefit could be coun-
terbalanced by toxicity, a careful follow-up is recommended. The
above-described selection factors should probably be restricted to
patients being offered single agent irinotecan, at least until similar
prognostic analyses will be available in patients receiving other
drugs or combinations.
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